These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI). Sun Y; Jia X; Gao Q; Liu X; Hou L IUBMB Life; 2017 Jan; 69(1):16-21. PubMed ID: 27862841 [TBL] [Abstract][Full Text] [Related]
4. Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells. Vlčková K; Vachtenheim J; Réda J; Horák P; Ondrušová L J Cell Mol Med; 2018 Apr; 22(4):2240-2251. PubMed ID: 29369499 [TBL] [Abstract][Full Text] [Related]
5. The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness. Schmidt U; Heller G; Timelthaler G; Heffeter P; Somodi Z; Schweifer N; Sibilia M; Berger W; Csiszar A J Exp Clin Cancer Res; 2021 Feb; 40(1):69. PubMed ID: 33596971 [TBL] [Abstract][Full Text] [Related]
6. Covalent dimerization of interleukin-like epithelial-to-mesenchymal transition (EMT) inducer (ILEI) facilitates EMT, invasion, and late aspects of metastasis. Kral M; Klimek C; Kutay B; Timelthaler G; Lendl T; Neuditschko B; Gerner C; Sibilia M; Csiszar A FEBS J; 2017 Oct; 284(20):3484-3505. PubMed ID: 28837266 [TBL] [Abstract][Full Text] [Related]
7. SOX5 is involved in balanced MITF regulation in human melanoma cells. Kordaß T; Weber CE; Oswald M; Ast V; Bernhardt M; Novak D; Utikal J; Eichmüller SB; König R BMC Med Genomics; 2016 Feb; 9():10. PubMed ID: 26927636 [TBL] [Abstract][Full Text] [Related]
8. The interleukin-like epithelial-mesenchymal transition inducer ILEI exhibits a non-interleukin-like fold and is active as a domain-swapped dimer. Jansson AM; Csiszar A; Maier J; Nyström AC; Ax E; Johansson P; Schiavone LH J Biol Chem; 2017 Sep; 292(37):15501-15511. PubMed ID: 28751379 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Anghel SI; Correa-Rocha R; Budinska E; Boligan KF; Abraham S; Colombetti S; Fontao L; Mariotti A; Rimoldi D; Ghanem GE; Fisher DE; Lévy F; Delorenzi M; Piguet V Pigment Cell Melanoma Res; 2012 Jul; 25(4):482-7. PubMed ID: 22594792 [TBL] [Abstract][Full Text] [Related]
10. MITF, the Janus transcription factor of melanoma. Koludrovic D; Davidson I Future Oncol; 2013 Feb; 9(2):235-44. PubMed ID: 23414473 [TBL] [Abstract][Full Text] [Related]
11. PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. He S; Li CG; Slobbe L; Glover A; Marshall E; Baguley BC; Eccles MR Melanoma Res; 2011 Feb; 21(1):24-34. PubMed ID: 21164369 [TBL] [Abstract][Full Text] [Related]
12. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways. Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358 [TBL] [Abstract][Full Text] [Related]
13. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation. Vachtenheim J; Ondrušová L Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058 [TBL] [Abstract][Full Text] [Related]
14. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma. Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625 [TBL] [Abstract][Full Text] [Related]
15. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value. Wouters J; Stas M; Govaere O; Barrette K; Dudek A; Vankelecom H; Haydu LE; Thompson JF; Scolyer RA; van den Oord JJ Mod Pathol; 2014 Aug; 27(8):1088-100. PubMed ID: 24390218 [TBL] [Abstract][Full Text] [Related]
16. Ennen M; Keime C; Gambi G; Kieny A; Coassolo S; Thibault-Carpentier C; Margerin-Schaller F; Davidson G; Vagne C; Lipsker D; Davidson I Clin Cancer Res; 2017 Nov; 23(22):7097-7107. PubMed ID: 28855355 [No Abstract] [Full Text] [Related]
17. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Carreira S; Goodall J; Denat L; Rodriguez M; Nuciforo P; Hoek KS; Testori A; Larue L; Goding CR Genes Dev; 2006 Dec; 20(24):3426-39. PubMed ID: 17182868 [TBL] [Abstract][Full Text] [Related]
19. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549. Song Q; Sheng W; Zhang X; Jiao S; Li F Tumour Biol; 2014 Feb; 35(2):1377-82. PubMed ID: 24072492 [TBL] [Abstract][Full Text] [Related]
20. STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. Swoboda A; Soukup R; Eckel O; Kinslechner K; Wingelhofer B; Schörghofer D; Sternberg C; Pham HTT; Vallianou M; Horvath J; Stoiber D; Kenner L; Larue L; Poli V; Beermann F; Yokota T; Kubicek S; Krausgruber T; Rendeiro AF; Bock C; Zenz R; Kovacic B; Aberger F; Hengstschläger M; Petzelbauer P; Mikula M; Moriggl R Oncogene; 2021 Feb; 40(6):1091-1105. PubMed ID: 33323974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]